Sign in
4

Changes in Ownership

ARROWHEAD PHARMACEUTICALS, INC. Filed Acc 0001209191-20-013488

Chief Financial Officer acquired 43,445 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Myszkowski Kenneth Allen Chief Financial Officer 2020-02-25 Option exercise +12,000 $9.90 $118,800 396,223 D: show line 1 in the form
Myszkowski Kenneth Allen Chief Financial Officer 2020-02-25 Option exercise +2,000 $5.19 $10,380 398,223 D: show line 2 in the form
Myszkowski Kenneth Allen Chief Financial Officer 2020-02-25 Option exercise +6,495 $14.54 $94,437 404,718 D: show line 3 in the form
Myszkowski Kenneth Allen Chief Financial Officer 2020-02-25 Option exercise +12,116 $7.75 $93,899 416,834 D: show line 4 in the form
Myszkowski Kenneth Allen Chief Financial Officer 2020-02-25 Option exercise +10,834 $6.15 $66,629 427,668 D: show line 5 in the form

Table II: Derivative

Insider Date Transaction Shares Price Value Owned after D/I
Myszkowski Kenneth Allen Chief Financial Officer 2020-02-25 Option exercise · Stock Option (right to buy) −12,000 104,116 D: show line 6 in the form
Myszkowski Kenneth Allen Chief Financial Officer 2020-02-25 Option exercise · Stock Option (right to buy) −2,000 102,116 D: show line 7 in the form
Myszkowski Kenneth Allen Chief Financial Officer 2020-02-25 Option exercise · Stock Option (right to buy) −6,495 95,621 D: show line 8 in the form
Myszkowski Kenneth Allen Chief Financial Officer 2020-02-25 Option exercise · Stock Option (right to buy) −12,116 83,505 D: show line 9 in the form
Myszkowski Kenneth Allen Chief Financial Officer 2020-02-25 Option exercise · Stock Option (right to buy) −10,834 72,671 D: show line 10 in the form
Loading xslF345X03/doc4.xml…